Skip to main
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics is a promising biotechnology company due to its leading product candidate, PrimeC, a novel extended-release, oral formulation for neurodegenerative diseases. The company has made significant strides in improving its regulatory and clinical positioning, with a potential NOC/c pathway submission and upcoming data readouts for Alzheimer's disease. However, investors may remain focused on the company's near-term capital needs, which may require additional financing to fund late-stage development. Nevertheless, the recent JAMA publication and additional data presentations have further strengthened the company's credibility and potential for partnerships and regulatory alignment in the future. With a strong focus on multiple indications and mechanisms, NeuroSense is poised for success through key catalysts in the coming years.

Bears say

NeuroSense Therapeutics is making progress with its product candidate, PrimeC, and has received FDA clearance for its Phase 3 program and published positive data. However, the company's year-end cash position is concerning and leaves financing risk as the most pressing issue. Despite the potential for PrimeC as a differentiated neurodegenerative treatment, the company's tight balance sheet could hinder its future success.

NRSN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 2 analysts, NRSN has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.